Acrivon Therapeutics: Can You Win In Clinical Trials With Selection Bias?
- Acrivon Therapeutics, Inc. is an oncology-focused biotech using a multi-targeted panel to identify patients for clinical trials. Acrivon Therapeutics is focused on ACR-368, a CHK1/2 inhibitor, with promising results in gynecologic cancers using their OncoSignature platform. Financially stable with $112.1 million in assets, Acrivon Therapeutics CRV has the potential for accelerated approval and future pipeline expansion.
- 06/13/2024
|
Is Acrivon Therapeutics, Inc. (ACRV) Outperforming Other Medical Stocks This Year?
- Here is how Acrivon Therapeutics, Inc. (ACRV) and Hims & Hers Health, Inc. (HIMS) have performed compared to their sector so far this year.
- 06/05/2024
|
Acrivon Therapeutics to Present at the Jefferies Global Healthcare Conference
- WATERTOWN, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics (AP3), today announced the company's president and chief executive officer, Peter Blume-Jensen, M.D., Ph.D., will participate in a fireside chat on Wednesday, June 5, 2024 at 9:30 a.m. ET at the Jefferies Global Healthcare Conference in New York.
- 05/29/2024
|
Here's Why You Should Buy Acrivon Therapeutics (ACRV) Stock
- Here, we discuss some reasons why buying Acrivon Therapeutics (ACRV) stock now may turn out to be a prudent move.
- 05/28/2024
|
5 Small Drug Stocks to Buy From a Recovering Industry
- Innovation is expected to continue to drive the growth of the Zacks Medical-Drugs industry. HRTX, BVS, AQST, ACRV and CRDL may prove to be good additions to one's portfolio.
- 05/24/2024
|
Has Acrivon Therapeutics, Inc. (ACRV) Outpaced Other Medical Stocks This Year?
- Here is how Acrivon Therapeutics, Inc. (ACRV) and ANI Pharmaceuticals (ANIP) have performed compared to their sector so far this year.
- 05/20/2024
|
Acrivon Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
- WATERTOWN, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics (AP3), today reported financial results for the first quarter ended March 31, 2024 and reviewed business highlights.
- 05/14/2024
|
Is a Surprise Coming for Acrivon Therapeutics (ACRV) This Earnings Season?
- Acrivon Therapeutics (ACRV) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
- 05/10/2024
|
Acrivon Therapeutics' shares climb 14% on plans to present cancer-test data
- Shares of Acrivon Therapeutics ACRV, -3.26% advanced in post-market trading after the biopharmaceutical company said it would present clinical trial data in connection with a biomarker test for ovarian and endometrial cancers.
- 04/24/2024
|
Acrivon Therapeutics Reports Initial Positive Clinical Data for ACR-368 and Pipeline Program Progress Today at Corporate R&D Event
- • Initial ACR-368 Phase 2b clinical data in patients with ovarian or endometrial cancers (n=26; 10 OncoSignature-positive and 16 OncoSignature-negative) are being presented• A 50% confirmed overall response rate observed with ACR-368 in OncoSignature-positive gynecological (ovarian and endometrial) cancers• Initial clinical validation of AP3 patient selection platform, demonstrated ability to prospectively predict ACR-368 RECIST responders (p-value = 0.0038)• ACR-2316, a potential first-in-class dual WEE1/PKMYT1 inhibitor, IND timeline accelerated with filing now expected in Q3 2024• Acrivon hosts Corporate R&D event webcast today at 4:15 pm ET
- 04/24/2024
|
Buffett Grabs More of This Stock, Plus Other Notable Insider Buying
- At the end of the previous week, the Oracle of Omaha yet again boosted his stake in a media giant's tracking stocks, even with shares still in retreat.
- 04/21/2024
|
Acrivon Therapeutics to Host Corporate R&D Event Highlighting AP3 and Pipeline Progress, Including Ongoing Prospective Validation of ACR-368 OncoSignature with Initial Phase 2 Data for ACR-368, and Preclinical Progress for ACR-2316
- WATERTOWN, Mass., April 16, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics (AP3), today announced it will be holding a virtual corporate R&D event on April 24th, 2024 from 4:15 p.m. to 5:30 p.m. ET. The agenda will feature presentations by Acrivon's leadership team followed by an interactive Q&A session.
- 04/16/2024
|
Acrivon Therapeutics Presents Data at AACR Annual Meeting Highlighting the Capabilities of Acrivon Predictive Precision Proteomics (AP3) for the Discovery of ACR-2316, a Novel, Selective WEE1/PKMYT1 Inhibitor, and the Identification of Actionable Resistance Mechanisms to ACR-368
- ACR-2316, which was internally discovered using biological SAR enabled by AP3 to overcome limitations of benchmark clinical WEE1 and PKMYT1 inhibitors, demonstrates potent anticancer activity in preclinical studies and is planned for monotherapy clinical development
- 04/10/2024
|
ACRV Stock Jumps 55% as Acrivon Therapeutics Gets $130 Million Boost
- Acrivon Therapeutics (NASDAQ: ACRV ) stock is rocketing higher on Tuesday after the clinical-stage biopharmaceutical company announced a $130 million private placement. This new funding comes from a private investment in public equity (PIPE) with existing and new accredited investors.
- 04/09/2024
|
Acrivon Therapeutics Announces $130 Million Private Placement Financing
- WATERTOWN, Mass, April 09, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics (AP3), today announced that it has entered into a securities purchase agreement with certain existing and new accredited investors to issue and sell an aggregate of 8,235,000 shares of its common stock at a price of $8.50 per share, a premium to the closing price on April 8, 2024, and pre-funded warrants to purchase up to an aggregate of 7,060,000 shares of common stock at a purchase price of $8.499 per pre-funded warrant, through a private investment in public equity (“PIPE”) financing. The pre-funded warrants will have an exercise price of $0.001 per share of common stock, be immediately exercisable and remain exercisable until exercised in full.
- 04/09/2024
|
What To Buy After You Sell The Russell 2000
- What To Buy After You Sell The Russell 2000
- 04/03/2024
|
Acrivon Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
- WATERTOWN, Mass., March 28, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics (AP3), today reported financial results for the fourth quarter and full year ended December 31, 2023 and provided business highlights.
- 03/28/2024
|
Acrivon Therapeutics to Present Data at AACR Annual Meeting Demonstrating Power of Acrivon Predictive Precision Proteomics (AP3) Platform and its Internally-Discovered, Potent WEE1/PKMYT1 Development Candidate, ACR-2316
- ACR-2316, a novel, selective dual WEE1 and PKMYT1 inhibitor development candidate, designed using AP3 to achieve superior single agent activity, demonstrates potent preclinical activity across studies
- 03/05/2024
|
Acrivon Therapeutics to Participate in a Panel Discussion at the TD Cowen 44th Annual Health Care Conference
- WATERTOWN, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics (AP3), today announced the company's president and chief executive officer, Peter Blume-Jensen, M.D., Ph.D., will participate in a panel entitled “Gynecological Cancers Corporate Panel Discussion” on Tuesday, March 5, 2024 at 10:30 a.m. ET at the TD Cowen 44th Annual Health Care Conference in Boston, MA.
- 02/27/2024
|
Acrivon Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
- WATERTOWN, Mass., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics (AP3), today announced the company's president and chief executive officer, Peter Blume-Jensen, M.D., Ph.D., will participate in a fireside chat on Tuesday, February 13, 2024 at 2:40 p.m. ET at the Oppenheimer 34th Annual Healthcare Life Sciences Conference.
- 02/06/2024
|
Acrivon Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- WATERTOWN, Mass., Jan. 12, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics or AP3, announced that the company approved a grant of an equity award under its 2023 Inducement Plan to one employee. The equity award was granted in the form of stock options and has a grant date of January 11, 2024.
- 01/12/2024
|
Acrivon Therapeutics to Present at the Piper Sandler Annual Healthcare Conference
- WATERTOWN, Mass., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics or AP3, today announced the company's president and chief executive officer, Peter Blume-Jensen, M.D., Ph.D., will participate in a fireside chat on Tuesday, November 28, 2023 at 8:30 a.m. ET at the Piper Sandler 35th Annual Healthcare Conference in New York, NY.
- 11/21/2023
|
Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- WATERTOWN, Mass., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics or AP3, announced that the company approved a grant of equity award under its 2023 Inducement Plan to one employee. The equity award was granted in the form of stock options and has a grant date of November 17, 2023.
- 11/21/2023
|
Acrivon Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights
- WATERTOWN, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, today reported financial results for the third quarter ended September 30, 2023 and provided business highlights.
- 11/09/2023
|
Acrivon Therapeutics Presents Data Demonstrating Capabilities of its AP3 Platform and ACR-368 OncoSignature Assay for Patient Responder Identification at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
- Data presented on the application of Acrivon Predictive Precision Proteomics (AP3) for the successful development and extensive evaluation of the ACR-368-tailored, proteomics-based OncoSignature assay for the prediction of patients, as well as tumor types, most likely to respond to the CHK1/2 inhibitor ACR-368
- 10/16/2023
|
Acrivon Therapeutics to Participate in Two Investor Conferences in September
- WATERTOWN, Mass., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, today announced the company's management team will participate in two investor conferences in September.
- 08/30/2023
|
7 Up-and-Coming Stocks to Buy for the Next Decade
- In arguably most cases involving expert financial advice, you will encounter guidance toward established enterprises, not up-and-coming stocks to buy. While the latter category certainly dials up the heat in terms of overall sexiness, some folks just can't handle adventurous portfolios.
- 06/29/2023
|
Acrivon Therapeutics to Present at the Jefferies Healthcare Conference
- WATERTOWN, Mass., June 02, 2023 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, today announced the company's president and chief executive officer, Peter Blume-Jensen, M.D., Ph.D., will participate in a fireside chat on Thursday, June 8, 2023 at 8:00 a.m. ET at the Jefferies Healthcare Conference in New York.
- 06/02/2023
|
Acrivon Therapeutics to Present at the H.C. Wainwright BioConnect Investor Conference
- WATERTOWN, Mass., April 25, 2023 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, today announced the company's chief executive officer and president, Peter Blume-Jensen, M.D., Ph.D., will participate in a fireside chat on Tuesday, May 2, 2023 at 3:00 p.m. ET at the H.C. Wainwright BioConnect Investor Conference in New York.
- 04/25/2023
|
Acrivon Therapeutics to Present at the Stifel 2023 Targeted Oncology Days Conference
- WATERTOWN, Mass., April 18, 2023 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, today announced the company's chief executive officer and president, Peter Blume-Jensen, M.D., Ph.D., will participate in a fireside chat on Tuesday, April 25, 2023 at 3:00 p.m. ET at the Stifel 2023 Targeted Oncology Days Conference taking place virtually.
- 04/18/2023
|
Acrivon: Precision-Testing Your Trial Patients Before Enrolment
- ACRV has a platform that tests trial patients for sensitivity to a tested drug before enrolling them. This way, it aims to make phase 2 trials more efficient.
- 03/26/2023
|
Acrivon Therapeutics to Present at the Oppenheimer 33rd Annual Healthcare Conference
- WATERTOWN, Mass., March 06, 2023 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, today announced the company's chief executive officer and president, Peter Blume-Jensen, M.D., Ph.D., will present a company overview on Monday, March 13, 2023 at 3:20 p.m. ET at the Oppenheimer 33rd Annual Healthcare Conference taking place virtually.
- 03/06/2023
|
Acrivon Therapeutics sets IPO price range
- Acrivon Therapeutics Inc. on Thursday set an estimated price range of $16 to $18 a share in its upcoming initial public offering (IPO) on the Nasdaq under the symbol ACRV. With 5.9 million shares in the IPO, Acrivon Therapeutics will raise $100 million based on the midpoint of its estimated price range.
- 11/03/2022
|
